A New Era in Brain Cancer Treatment
Brain-based cancers like Glioblastoma Multiforme (GBM) remain among the most challenging to treat, with exceptionally low survivability rates. NeOnc’s formulations are actively working to change those odds for patients globally by providing a solution that overcomes existing limitations.
This solution is centered on our proprietary Perillyl Alcohol (POH) technology. The unique, lipophilic properties of POH enable our formulations to effectively pass through the Blood-Brain Barrier (BBB), the primary impediment to effective pharmaceutical treatment for brain-based cancers. Our innovative technology offers three distinct delivery methodologies, giving physicians precise options to ensure prescribed therapeutics reach the patient with the highest potential for cure.
This advanced approach to delivering therapeutics for Central Nervous System (CNS)- based cancers mitigates the inherent issues of current methodologies, truly leveling the playing field and creating a more effective path to treatment.
The primary hurdle in effectively treating CNS cancers isn’t just a lack of better drugs; it’s getting therapeutics to the brain without compromising their ability to cure. This critical barrier is the Blood-Brain Barrier (BBB).
The BBB is the brain’s natural defense, blocking large molecules like viruses and neurotoxins. Unfortunately, it also prevents beneficial agents, such as chemotherapeutics, from reaching tumor sites within the brain.
NeOnc has discovered a potential solution to this long-standing problem, actively working to transform pharma-based CNS disease treatment.
Enhanced Delivery
The foundation of NeOnc’s innovative discoveries lies in our ability to provide superior delivery options for pharma-therapeutics, significantly enhancing the efficacy of drugs designed to treat CNS-based diseases.
